Literature DB >> 8862587

Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.

L A Mitchell1, M K Ho, J E Rogers, A J Tingle, R G Marusyk, J M Weber, P Duclos, M L Tepper, M Lacroix, M Zrein.   

Abstract

Rubella virus (RV)-specific immunoglobulin G (IgG) antibodies were studied in military recruits undergoing unselected immunization with live attenuated measles, mumps, and rubella virus (MMR) vaccine. Three different whole-RV enzyme immunoassays (EIAs) and an epitope-specific EIA with a synthetic peptide (BCH-178c) representing a heutralization domain on the RV E1 envelope protein were used. Before vaccination, 84.2, 87.7, and 84.5% of the subjects tested (n = 399) were found to be seropositive (> 10 IU/ml or assay equivalent) by the three whole-RV EIAs, respectively, while only 82.5% were seropositive by the BCH-178c EIA. Although prevaccination seropositivity rates were similar for the whole-RV EIAs (sensitivity, 94 to 100%), many sera considered seropositive by the whole-RV EIAs had E1 peptide EIA antibody levels of < 10 IU/ml (sensitivity, 77.4 to 80.7%). One month after vaccination, 97.8, 97.2, and 93.5% of the subjects who were followed (n = 356) were seropositive by the three whole-RV EIAs, respectively, while 89% had BCH-178c peptide-specific IgG titers of > 10 IU/ml. After vaccination, depending on the assay used, up to 20.6% of initially seropositive individuals exhibited a greater than fourfold increase in RV-specific IgG, while up to 47.3% showed a greater than twofold increase. Increased antibody titers after vaccination (seroboosting) were most frequently associated with low levels of BCH-178c peptide-specific IgG before vaccination. RV protein-specific IgG was also studied by immunoblot assays in a subset (n = 56) of individuals receiving the MMR vaccine. Of these, 89.4 and 91.1% exhibited RV protein (E1, E2, and C protein)-specific IgG before and after vaccination, respectively. Seroboosting (two- to fourfold increase in EIA titers of individuals seropositive by the whole-RV EIA before vaccination) was usually accompanied by a shift in the IgG immunoblot pattern from a single (E1) to multiple (E1-E1, E1-C, or E1-E2-C) specificities, suggesting exposure of new epitopes as a result of viral replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862587      PMCID: PMC229219          DOI: 10.1128/jcm.34.9.2210-2218.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals.

Authors:  A Schluederberg; D M Horstmann; W A Andiman; M F Randolph
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

2.  Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children.

Authors:  K Naficy; R Nategh; S Ahangary; H Mohsenin
Journal:  Am J Dis Child       Date:  1970-12

3.  How well do low levels of rubella antibody protect?

Authors:  S O'Shea; G Parsons; J M Best; J E Banatvala; H H Balfour
Journal:  Lancet       Date:  1981-12-05       Impact factor: 79.321

4.  Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines.

Authors:  L Grillner
Journal:  Scand J Infect Dis       Date:  1975

5.  Consequences of confirmed maternal rubella at successive stages of pregnancy.

Authors:  E Miller; J E Cradock-Watson; T M Pollock
Journal:  Lancet       Date:  1982-10-09       Impact factor: 79.321

6.  Rubella viraemia and antibody responses after rubella vaccination and reimmunization.

Authors:  H H Balfour; K E Groth; C K Edelman; D P Amren; J M Best; J E Banatvala
Journal:  Lancet       Date:  1981-05-16       Impact factor: 79.321

7.  Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized.

Authors:  R G Robinson; F E Dudenhoeffer; H J Holroyd; L R Baker; D I Bernstein; J D Cherry
Journal:  J Pediatr       Date:  1982-08       Impact factor: 4.406

8.  Response to experimental challenge in persons immunized with different rubella vaccines.

Authors:  A Fogel; C B Gerichter; B Barnea; R Handsher; E Heeger
Journal:  J Pediatr       Date:  1978-01       Impact factor: 4.406

9.  Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus.

Authors:  S O'Shea; J M Best; J E Banatvala
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

Review 10.  Molecular biology of rubella virus.

Authors:  T K Frey
Journal:  Adv Virus Res       Date:  1994       Impact factor: 9.937

View more
  6 in total

1.  Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status.

Authors:  P Cordoba; A Lanoel; S Grutadauria; M Zapata
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Barbara Francis; Nicholas Laven; Joan Marler; David Dickeson; Tony Panayotou; Kim Wilson; Robyn Wootten; Elizabeth M Dax
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

Review 3.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

4.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

Review 5.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

6.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.